Tango Therapeutics, Inc. (NASDAQ:TNGX)
Industry: Biotechnology

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Current Quote*
Last: $13.010
Change: 2.000
Book: $1.794
Volume: 5,949,324

As Of: 01/16 16:23 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol TNGX

Graphs for TNGX


3 Month Graph


6 Month Graph


1 Year Graph